Skip to main content
SpringerLink
Log in

Promoting informed decision making about prostate cancer screening

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

Because prostate cancer screening with prostate specific antigen is controversial, informed consent is recommended. Physicians are encouraged to discuss facts about prostate specific antigen with patients and to supplement such discussions with informational brochures or videotapes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33.

    PubMed  CAS  Google Scholar 

  2. American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology. 2000;14:267–72, 277–280.

    Google Scholar 

  3. Ries LA, Hankey BF, Miller BA, et al. (eds). Cancer Statistics Review 1973–1988. Bethesda, MD: National Cancer Institute; 1991. NIH publication 91-2789.

    Google Scholar 

  4. Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer: I. Prior probability and effectiveness of tests. Ann Intern Med. 1997;126:394–406.

    PubMed  CAS  Google Scholar 

  5. Woolf SH, Screening for prostate cancer with prostate-specific antigen: An examination of the evidence. N Engl J Med. 1995;333:1401–1405.

    Article  PubMed  CAS  Google Scholar 

  6. Eschenbach AV, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 1997. CA Cancer J Clin. 1997;47:261–264.

    Google Scholar 

  7. Physician Data Query [computer database]. Prostate Cancer Screening State-of-the-Art Statement. Bethesda, MD: National Cancer Institute; 1996.

    Google Scholar 

  8. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed., Baltimore, MD: Williams & Wilkins; 1996.

    Google Scholar 

  9. Coley CM, Barry MJ, Mulley AG. Clinical Guideline; Part III. Screening for prostate cancer. Ann Intern Med. 1997; 126:480–484.

    Google Scholar 

  10. American Academy of Family Physicians. Summary of recommendations for periodic health examination. Available at: http://www.aafp.org/exam/app-d_c.html. Accessed December 3, 1999.

  11. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurement. JAMA. 1997; 277:1452–1455.

    Article  PubMed  CAS  Google Scholar 

  12. Brawer MK. Prostate-specific antigen: current status. CA Cancer J Clin. 1999;49:264–81.

    PubMed  CAS  Google Scholar 

  13. Oesterling JE, Cooner WH, Jacobsen SJ, et al. Influence of patient age on the serum PSA concentration: an important clinical observation. Urol Clin North Am. 1993;20:671–680.

    PubMed  CAS  Google Scholar 

  14. Carter HB, Pearson JD, Metter J, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215–2220.

    Article  PubMed  CAS  Google Scholar 

  15. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167–170.

    Article  PubMed  CAS  Google Scholar 

  16. Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 1999;161: 529–533.

    Article  PubMed  CAS  Google Scholar 

  17. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: Interpreting trends in prostate cancer. Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017–1024.

    Article  PubMed  CAS  Google Scholar 

  18. Brawley OW. Prostate cancer screening: a note of caution. In: Thompson IM, Resnick MI, Klein EJ, eds. Screening for Prostate Cancer. Totowa, NJ: Humana Press, Inc. In Press.

  19. Legler JM, Feuer EJ, Potosky AL, et al. The role of prostate-specific antigen (PSA) testing in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 1988. 1998:9:519–527.

    Article  CAS  Google Scholar 

  20. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer—Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91: 1025–1032.

    Article  PubMed  CAS  Google Scholar 

  21. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we known and what we need to known. Ann Intern Med. 1993;119:914–923.

    PubMed  CAS  Google Scholar 

  22. Gohagan JK, Prorok PC, Kramer BS, et al. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. J. Urol. 1994;152;1905–1909.

    PubMed  CAS  Google Scholar 

  23. Prorok PC. The National Cancer Institute Multi-Screening Trial. Can J Oncol. 1994;4(Suppl 1):98–101.

    PubMed  Google Scholar 

  24. Schroder FH. The European Screening Study for Prostate Cancer. Can J Oncol. 1994;4(Suppl 1):102–109.

    PubMed  Google Scholar 

  25. Schroder FH, Kranse R, Rietbergen J. et al. The European randomized study of screening for prostate cancer (ERSPC): an update. Eur Urol. 1999;35:539–543.

    Article  PubMed  CAS  Google Scholar 

  26. Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer. II. Estimating the risks, benefits, and costs. Ann Intern Med. 1997;126:468–479.

    PubMed  CAS  Google Scholar 

  27. Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer. A decision analytic view. JAMA. 1994272: 773–780.

    Article  PubMed  CAS  Google Scholar 

  28. Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical prostatectomy: The John Hopkins experience after 10 years. Urol Clin North Am. 1993;20:713–725.

    PubMed  CAS  Google Scholar 

  29. Walsh PC. Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med. 1993;119:948–949.

    PubMed  CAS  Google Scholar 

  30. Bartsch G, Horninger W, Klocker H, et al. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria [Abstract]. J. Urol. 2000;163(Suppl):88 Abstract 387.

    Google Scholar 

  31. Labrie F, Candas B, Dupont A. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999;38:83–91.

    Article  PubMed  CAS  Google Scholar 

  32. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289–294.

    Article  PubMed  CAS  Google Scholar 

  33. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948–954.

    Article  PubMed  CAS  Google Scholar 

  34. Walsh PC, Brooks JD. The Swedish prostate cancer paradox. JAMA 1997;277:497–498.

    Article  PubMed  CAS  Google Scholar 

  35. Myers RE, Chodak GW, Wolf TA, et al. Adherence by African American men to prostate cancer education and early detection. Cancer. 1999;86:88–104.

    Article  PubMed  CAS  Google Scholar 

  36. Eddy DM. Screening for lung cancer. Ann Intern Med. 1989; 111:232–237.

    PubMed  CAS  Google Scholar 

  37. Collins MM, Barry MJ. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate. JAMA. 1996;276:1976–1979.

    Article  PubMed  CAS  Google Scholar 

  38. Middleton RG. Prostate cancer: are we screening and treating too much? Ann Intern Med. 1997;126:465–467.

    PubMed  CAS  Google Scholar 

  39. Glode LM. Prostate cancer screening: a place for informed consent? Hosp Pract. Sept 1994:8–12.

  40. Brett AS. The mammography and prostate-specific antigen controversies: implication for patient-physician encounters and public policy. J Gen Intern Med. 1995;10:266–270.

    Article  PubMed  CAS  Google Scholar 

  41. Hicks RJ, Hamm RM, Bemben DA. Prostate cancer screening: what family physicians believe is best. Arch Fam Med. 1995;4:317–322.

    Article  PubMed  CAS  Google Scholar 

  42. McKnight JT, Tietze PH, Adcock BB, Maxwell AJ, Smith WO, Nagy MC. Screening for prostate cancer: a comparison of urologists and primary care physicians. Southern Med. J. 1996;89:885–888.

    CAS  Google Scholar 

  43. Williams RB, Boles M, Johnson RE. Use of prostate-specific antigen for prostate cancer screening in primary care practice. Arch Fam Med. 1995;4:311–315.

    Article  PubMed  CAS  Google Scholar 

  44. Hoffman RM, Blume P, Gilliland F. Prostate-specific antigen testing practices and outcomes. J Gen Intern Med. 1998;13: 106–110.

    Article  PubMed  CAS  Google Scholar 

  45. Federman DG, Goyal S, Kamina A, Peduzzi P, Concato J. Informed consent for PSA screening: does it happen? Effective Clin Practice. 1999;2:152–157.

    CAS  Google Scholar 

  46. O'Dell KJ, Volk RJ, Cass AR, et al. Screening for prostate cancer with the prostate-specific antigen test. Are patients making informed decisions? J Fam Pract. 1999;48:682–688.

    PubMed  Google Scholar 

  47. Diefenbach PN, Ganz PA, Pawlow AJ, Guthrie D. Screening by the prostate-specific antigen test: What do the patients know? J Cancer Educ. 1996;11:39–44.

    PubMed  CAS  Google Scholar 

  48. Mainous AG III, Hagen MD. Public awareness of prostate cancer and the prostate-specific antigen test. Cancer Pract. 1994;2:217–221.

    PubMed  Google Scholar 

  49. Demark-Wahnefried W, Strigo T, et al. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology. 1995;46:346–351.

    Article  PubMed  CAS  Google Scholar 

  50. Barber KR, Shaw R, Folts M, et al. Differences between African American and Caucasian men participating in a community-based prostate cancer screening program. J Community Health. 1998;23:441–451.

    Article  PubMed  CAS  Google Scholar 

  51. Smith GE, DeHaven MJ, Grundig JP, Wilson GR. African-American males and prostate cancer: assessing knowledge levels in the community. J Natl Med Assoc. 1997;89:387–391.

    PubMed  CAS  Google Scholar 

  52. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1999. CA Cancer J Clin. 1999;49:8–31.

    PubMed  CAS  Google Scholar 

  53. Powell IJ. Prostate cancer and African American men. Oncology. 1997;11:599–615.

    PubMed  CAS  Google Scholar 

  54. Brawn PN, Johnson EH, Kuhl DL, et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer. 1993;72:2569–2573.

    Article  Google Scholar 

  55. Natarajan N, Murphy GP, Mettlin C. Prostate cancer in blacks: an update from the American College of Surgeons' patterns of care studies. J Surg Oncol. 1989;40:232–236.

    Article  PubMed  CAS  Google Scholar 

  56. Bradcock CH, Edwards KA, Hasenberg NM. Informed decision making in outpatient practice. Time to get back to basics. JAMA. 1999;282:2313–2320.

    Article  Google Scholar 

  57. Barry MJ. Involving patients in medical decisions. How can physicians do better? JAMA. 1999;282:2322–2329.

    Article  Google Scholar 

  58. Chan E. Informed consent and prostate specific antigen screening: what patients ought to know. In: Thompson IM, Resnick MI, Klein EJ, eds. Screening for Prostate Cancer. Totowa, NJ: Humana Press, Inc; In Press.

  59. Sprung CL, Winick BJ. Informed consent in theory and practice: Legal and medical perspectives on the informed consent doctrine and a proposed reconceptualization. Crit Care Med. 1989;17:1346–1354.

    Article  PubMed  CAS  Google Scholar 

  60. Hollander RD. Changes in the concept of informed consent in medical encounters. J Med Educ. 1984;59:783–788.

    PubMed  CAS  Google Scholar 

  61. Diem SJ. How and when should physicians discuss clinical decisions with patients? J Gen Intern Med. 1997;12:397–398.

    Article  PubMed  CAS  Google Scholar 

  62. Lidz CW, Appelbaum PS, Meisel A. Two models of implementing informed consent. Arch Intern Med. 1988;148:1385–1389.

    Article  PubMed  CAS  Google Scholar 

  63. Meisel A, Kuczewski M. Legal and ethical myths about informed consent. Arch Intern. Med. 1996;156:2521–2526.

    Article  PubMed  CAS  Google Scholar 

  64. Geller G, Botkin JR, Green MJ, et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA. 1997;277:1467–1474.

    Article  PubMed  CAS  Google Scholar 

  65. Volk RJ, Cantor SB, Spann SJ, Cass AR, Cardenas MP, Warren MM. Preferences of husbands and wives for prostate cancer screening. Arch Fam Med. 1997;6:72–76.

    Article  PubMed  CAS  Google Scholar 

  66. Emanuel EJ, Emanuel LL. Four models of the physician-patient relationship. JAMA. 1992;267:2221–2226.

    Article  PubMed  CAS  Google Scholar 

  67. Quill TE, Brody H. PatPhysician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med. 1996;125:763–769.

    PubMed  CAS  Google Scholar 

  68. President's Commission for the Study of Ethical Problems in Medicine and Biomedical Research. Making Health Care Decisions. Volume I. Washington, DC: US Government Printing Office; 1982.

    Google Scholar 

  69. Forrow L, Wartman SA, Brock DW. Science, ethics and the making of clinical decisions. Implications for risk factor intervention. JAMA. 1988;259:3161–3167.

    Article  PubMed  CAS  Google Scholar 

  70. Chan ECY, Sulmasy DP. What should men know about prostate-specific antigen screening before giving informed consent? Am J Med. 1998;105:266–274.

    Article  PubMed  CAS  Google Scholar 

  71. Rubenstein L. Strategies to overcome barriers to early detection of cancer among older adults. Cancer. 1994;74:2190–2193.

    Article  PubMed  CAS  Google Scholar 

  72. Stair J. Public awareness of screening programs. Oncol Nurs Forum. 1992;19:93–94.

    PubMed  CAS  Google Scholar 

  73. Faden RR, Beauchamp TL. A History and Theory of Informed Consent. New York, NY: Oxford University Press; 1986.

    Google Scholar 

  74. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 4th ed. New York, NY: Oxford University Press; 1994:120–188.

    Google Scholar 

  75. Bogardus ST, Holmboe E, Jekel JF. Perils, pitfalls, and possibilities in talking about medical risk. JAMA. 1999;28: 1037–1041.

    Article  Google Scholar 

  76. Edwards A, Elwyn G. The potential benefits of decision aids in clinical medicine. JAMA. 1999;282:779–780.

    Article  PubMed  CAS  Google Scholar 

  77. Rothman AJ, Kiviniemi MT. Treating people with information: an analysis and review of approaches to communicating health risk information. Monogr Natl Cancer Inst. 1999; 25:44–51.

    PubMed  Google Scholar 

  78. O'Connor AM, Fiset V, DeGrasse C, et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. Monogr Natl Cancer Inst. 1999;25:67–80.

    PubMed  Google Scholar 

  79. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation. A randomized controlled trial. JAMA, 1999;282:737–743.

    Article  PubMed  CAS  Google Scholar 

  80. Flood AB, Wennberg JE, Nease RF, Fowler FJ, Ding J, Hynes LM. Members of the Prostate Patient Outcomes Research Team. The importance of patient preference in the decision to screen for prostate cancer. J Gen Intern Med. 1996;11:342–349.

    Article  PubMed  CAS  Google Scholar 

  81. Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med. 1999;8:333–340.

    Article  PubMed  CAS  Google Scholar 

  82. Wolf A, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med. 1996;156:1333–1336.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General Internal Medicine, Department of Medicine, The University of Texas-Houston Health Science Center, 6431 Fannin, 1.122 MSB, 77030, Houston, TX, USA

    Evelyn C. Y. Chan MD, MS (Assistant Professor and Director)

Authors
  1. Evelyn C. Y. Chan MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Chan, E.C.Y. Promoting informed decision making about prostate cancer screening. Compr Ther 27, 195–201 (2001). https://doi.org/10.1007/s12019-001-0014-4

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-001-0014-4

Keywords

Search

Navigation